XML 31 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
License and Collaboration Agreements (Tables)
 6 Months Ended
Jun. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

 

 

 

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

Partner

 

Drug or Drug Candidate

 

2016

 

 

2015

 

 

2016

 

 

2015

 

AstraZeneca AB

 

MOVANTIKTM (NKTR-118)

and MOVANTIKTM fixed-dose

combination program

(NKTR-119)

 

$

—

 

 

$

—

 

 

$

28,000

 

 

$

90,000

 

Roche

 

PEGASYS® and MIRCERA®

 

 

1,919

 

 

 

3,197

 

 

 

3,842

 

 

 

6,408

 

Daiichi Sankyo Europe GmbH

 

ONZEALDTM (NKTR-102)

 

 

3,258

 

 

 

—

 

 

 

3,258

 

 

 

—

 

Amgen, Inc.

 

Neulasta®

 

 

1,250

 

 

 

1,250

 

 

 

2,500

 

 

 

2,500

 

Bayer Healthcare LLC

 

BAY41-6551

(Amikacin Inhale)

 

 

357

 

 

 

395

 

 

 

714

 

 

 

1,205

 

Baxalta Incorporated

 

ADYNOVATETM

 

 

207

 

 

 

88

 

 

 

313

 

 

 

197

 

Other

 

 

 

 

1,279

 

 

 

1,278

 

 

 

3,830

 

 

 

2,638

 

License, collaboration

    and other revenue

 

 

 

$

8,270

 

 

$

6,208

 

 

$

42,457

 

 

$

102,948